Binge eating – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:37:30 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Binge eating – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on BP1.4979 for Treating Binge Eating Disorder in Women with Moderate to Severe Symptoms https://clinicaltrials.eu/trial/study-on-bp1-4979-for-treating-binge-eating-disorder-in-women-with-moderate-to-severe-symptoms/ Mon, 04 May 2026 07:51:50 +0000 https://clinicaltrials.eu/trial/study-on-bp1-4979-for-treating-binge-eating-disorder-in-women-with-moderate-to-severe-symptoms/ This clinical trial is focused on studying a condition known as binge eating disorder, which involves regularly eating large amounts of food in a short period while feeling a lack of control over eating. The trial is testing a new treatment called BP1.4979, which is taken as a tablet. The purpose of the study is to evaluate how effective and safe this medication is for women with moderate to severe binge eating disorder.

Participants in the study will be given either the medication BP1.4979 or a matching film-coated placebo tablet. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not influenced by expectations about the treatment. The study will last for a period of eight weeks, during which participants will take the medication twice a day.

Throughout the study, participants will keep a diary to record their binge eating episodes. The main goal is to see if there is a change in the number of binge eating episodes per week from the start to the end of the study. Additionally, other aspects such as changes in dietary habits and overall impressions of improvement will be monitored. This trial aims to provide valuable information on whether BP1.4979 can be a helpful treatment for those struggling with binge eating disorder.

]]> Study on Hydrocortisone and Food Exposure Therapy for Patients with Binge Eating Disorder https://clinicaltrials.eu/trial/study-on-hydrocortisone-and-food-exposure-therapy-for-patients-with-binge-eating-disorder/ Wed, 29 Apr 2026 15:01:32 +0000 https://clinicaltrials.eu/trial/study-on-hydrocortisone-and-food-exposure-therapy-for-patients-with-binge-eating-disorder/ This clinical trial is focused on studying Binge Eating Disorder, a condition where individuals frequently consume large amounts of food and feel a lack of control over their eating habits. The study will explore the effectiveness of a treatment that combines food exposure therapy with a medication called Hydrocortisone. Hydrocortisone is a type of glucocorticoid, which is a hormone that can influence stress responses in the body. The trial will compare the effects of this combination treatment to a placebo, which is a substance with no active medication, to see if it helps reduce cravings for food in people with Binge Eating Disorder.

The purpose of the study is to determine if the combination of food exposure therapy and hydrocortisone is more effective than food exposure therapy alone in reducing food cravings. Participants will undergo sessions where they are exposed to real food while taking either hydrocortisone or a placebo. The study will monitor changes in food cravings, feelings of losing control over eating, and emotional responses to food over a period of time. The goal is to see if the treatment can help decrease the desire to binge eat and improve control over eating habits.

Participants will be involved in the study for a period that includes treatment sessions and follow-up assessments. The study will track the decrease in food cravings and other related behaviors both shortly after treatment and up to one month later. This research aims to provide insights into new ways to help individuals manage Binge Eating Disorder more effectively.

]]>